Ensysce Biosciences, Inc., a clinical-stage biotech company, engages in developing various prescription drugs. The company is developing tamper-proof opioids using Trypsin Activated Abuse Protection and Multi-Pill Abuse Resistance platforms. Its products treat severe pain and assist in preventing deaths caused by opioid abuse. The company is headquartered in La Jolla, California.
IPO Year:
Exchange: NASDAQ
Website: ensysce.com
Date | Price Target | Rating | Analyst |
---|---|---|---|
11/30/2021 | $4.00 | Buy | Lake Street |